Grifols, S.A. (GRFS) Stock Rating Lowered by UBS AG
Grifols, S.A. (NASDAQ:GRFS) was downgraded by stock analysts at UBS AG from an “outperform” rating to a “market perform” rating in a report issued on Friday.
Several other equities research analysts also recently weighed in on the company. Citigroup Inc. started coverage on Grifols, in a report on Tuesday, October 31st. They set a “buy” rating on the stock. BidaskClub downgraded Grifols, from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Finally, Zacks Investment Research downgraded Grifols, from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. Grifols, currently has an average rating of “Hold” and an average target price of $24.00.
Grifols, (NASDAQ GRFS) traded down $0.13 during midday trading on Friday, hitting $23.04. The company had a trading volume of 380,500 shares, compared to its average volume of 634,402. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17. Grifols, has a 12 month low of $14.33 and a 12 month high of $24.20. The firm has a market cap of $15,732.24, a P/E ratio of 21.33, a price-to-earnings-growth ratio of 1.68 and a beta of 1.07.
Large investors have recently made changes to their positions in the stock. Lenox Wealth Management Inc. raised its position in Grifols, by 8,372.9% during the 3rd quarter. Lenox Wealth Management Inc. now owns 5,931 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 5,861 shares during the last quarter. First Republic Investment Management Inc. bought a new position in Grifols, during the 3rd quarter worth $203,000. Advisory Services Network LLC raised its position in Grifols, by 26.2% during the 2nd quarter. Advisory Services Network LLC now owns 9,564 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,987 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Grifols, during the 2nd quarter worth $223,000. Finally, Stevens Capital Management LP bought a new position in Grifols, during the 2nd quarter worth $236,000. 22.63% of the stock is owned by institutional investors and hedge funds.
Grifols, Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.